A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer

Data for 372 adult patients with advanced non-small cell lung cancer. Treatment regime was standard chemotherapy with (n=185) or without (n=187) application of a nitroglycerin 25 mg patch. Study assessments were carried out at baseline before randomization, then every 3 weeks during chemotherapy, and every 4 weeks from completion of chemotherapy until disease progression. Dataset includes: Progression free survival, overall survival data, demographic data, diagnostic data, treatment data, quality of life data, objective tumour response. (RECIST 1.1), adverse events.